VP, Enzyme Therapies Business Unit, Clinical Science

Who We Are

Bio Marin is a global biotechnology company that relentlessly pursues bold science to translate genetic discoveries into new medicines that advance the future of human health.

Since our founding in 1997, we have applied our scientific expertise in understanding the underlying causes of genetic conditions to create transformative medicines, using a number of treatment modalities.

Using our unparalleled expertise in genetics and molecular biology, we develop medicines for patients with significant unmet medical need. We enlist the best of the best – people with the right technical expertise and a relentless drive to solve real problems – and create an environment that empowers our teams to pursue bold, innovative science. With this distinctive approach to drug discovery, we’ve produced a diverse pipeline of commercial, clinical and preclinical candidates that have well‑understood biology and provide an opportunity to be first‑to‑market or offer a substantial benefit over existing therapeutic options.

About Worldwide Research and Development:
From research and discovery to post‑market clinical development, our WWRD engine involves all bench and clinical research and the associated groups that support those endeavors. Our teams work on developing first‑in‑class and best‑in‑class therapeutics that provide meaningful advances to patients who live with genetic diseases.

Reporting to the Chief Research and Development Officer, Greg Friberg, the Vice President, Enzyme Therapies, Clinical Development is the head of Research & Development for Bio Marin’s Enzyme Therapies Business Unit (BU). This executive is responsible for the overall strategic direction, development, and lifecycle management of both current and future assets within the BU pipeline. As a member of both the BU Leadership Team and the R&D Leadership Team, the VP will drive cross‑functional strategy, partner closely with scientific, clinical, commercial, regulatory, business development, and portfolio strategy leaders, and ensure all BU activities are aligned to broader corporate objectives and maximize portfolio value.

She will oversee a team of 5‑10 physicians responsible for the clinical development of the business unit’s late‑stage programs and lifecycle management of its marketed products (including two in PKU and three ERTs, plus one from the Inozyme acquisition).

This leader is accountable for holistic pipeline optimization, including strategic selection, prioritization, and resource allocation across marketed products and new development candidates. The VP will ensure seamless integration of BU goals with enterprise ambitions, drive best‑in‑class therapy development, and maintain a clear focus on long‑term revenue growth, innovation, and sustainable impact.

Key responsibilities include:

• Strategic Leadership
  :
  Lead the development and execution of the Enzyme Therapies BU pipeline strategy, encompassing both lifecycle management of marketed products and development of future drug assets. Ensure all activities reflect corporate goals and deliver maximum portfolio value.
• Pipeline Optimization
  :
  Oversee strategic selection and prioritization of assets, balancing risk, investment, and return to optimize the BU pipeline and achieve or exceed Long Range Plan (LRP) goals for revenue and growth.
• Cross‑Functional Team Leadership
  :
  Build and lead a high‑performing, cross‑functional development strategy team, including clinicians and asset team leaders. Foster a culture of excellence, collaboration, and continuous improvement.
• Enterprise & Stakeholder Alignment
  :
  Partner with clinical, regulatory, commercial, medical, portfolio strategy, and business development functions to align asset prioritization, planning, and execution with near‑, mid‑, and long‑term revenue and growth ambitions.
• Lifecycle Management
  :
  Drive late‑stage clinical development, study design, and execution for pivotal and post‑marketing studies. Oversee lifecycle management of BU assets, including marketed products and new acquisitions.
• Business Development & External Innovation
  :
  Work closely with business development to evaluate and integrate external innovation…